Peregrine Pharmaceuticals Reports Progress In Its Phase II Trial Of Bavituximab Plus Docetaxel In Patients With Advanced Breast Cancer

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for cancer and serious viral infections, announced that updated preliminary data from the first stage of its Phase II trial evaluating bavituximab in combination with docetaxel showed that 10 of 14 (71%) evaluable breast cancer patients achieved an objective tumor response according to RECIST criteria.

More: continued here

Filed under: Breast Cancer on October 27th, 2008